A Study on the Application and Use of Artificial Intelligence to Support Drug Development

被引:53
|
作者
Lamberti, Mary Jo [1 ]
Wilkinson, Michael [1 ]
Donzanti, Bruce A. [2 ]
Wohlhieter, G. Erich [3 ]
Parikh, Sudip [4 ]
Wilkins, Robert G. [5 ]
Getz, Ken [1 ]
机构
[1] Tufts Univ, Sch Med, Tufts Ctr Study Drug Dev, Boston, MA 02111 USA
[2] Genentech Inc, Global Pharmacovigilance Innovat Policy, San Francisco, CA 94080 USA
[3] Amgen Inc, Digital Hlth & Innovat, Thousand Oaks, CA USA
[4] Drug Informat Assoc Amer, Washington, DC USA
[5] QPS Consulting LLC, Ashburn, VA USA
关键词
AI; artificial intelligence; drug development; machine learning; technology;
D O I
10.1016/j.clinthera.2019.05.018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: The Tufts Center for the Study of Drug Development (CSDD) and the Drug Information Association (DIA) in collaboration with 8 pharmaceutical and biotechnology companies conducted a study examining the adoption and effect of artificial intelligence (AI), such as machine learning, on drug development. The study was conducted to clarify and understand AI adoption across the industry and to gather detailed insights into the spectrum of activities included in the definition of AI. The study investigated and identified analytical platforms and innovations across pharmaceutical and biotechnology companies currently being used or planned for in the future. Methods: A 2-part method was used that comprised in-depth interviews with AI industry experts and a global survey conducted across pharmaceutical and biotechnology organizations. Eleven in-depth interviews focused on use and implementation of AI across drug development. The survey assessed use of AI and included perceptions about current and future use. The survey also examined technology definitions, assessment of organizational and personal AI expertise, and use of partnerships. A total of 402 responses, including data from 217 unique organizations, were analyzed. Findings: Although 7 in 10 respondents reported using AI in some capacity, a wide range of use was reported by AI type. Patient selection and recruitment for clinical studies was the most commonly reported AI activity, with 34 respondents currently using AI for this activity. In addition, identification of medicinal products data gathering was the top activity being piloted or in the planning stages, reported by 49 respondents. The study also revealed that the most significant challenges to AI implementation included staff skills (55%), data structure (52%), and budgets (49%). Nearly 60% of respondents noted planned increases in staff within 1-2 years to support AI use or implementation. Implications: Despite the challenges to AI implementation, the survey revealed that most organizations use AI in some capacity and that it is important to the success of an organization's workforce. Many organizations reported expectations for increasing staff as implementation of AI expands. Further research should examine the changing development landscape as the role of AI evolves. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:1414 / 1426
页数:13
相关论文
共 50 条
  • [21] Artificial Intelligence Effecting a Paradigm Shift in Drug Development
    Rashid, Masturah Bte Mohd Abdul
    SLAS TECHNOLOGY, 2021, 26 (01): : 3 - 15
  • [22] APPLICATION OF ARTIFICIAL INTELLIGENCE IN THE BUSINESS
    Buntak, Kresimir
    Kovacic, Matija
    Mutavdzija, Maja
    INTERNATIONAL JOURNAL FOR QUALITY RESEARCH, 2021, 15 (02) : 403 - 416
  • [23] Application and teaching of computer molecular simulation embedded technology and artificial intelligence in drug research and development
    Chen, Xiaoling
    Zhang, Junmin
    Zhao, Quanyi
    Ding, Li
    Wu, Zhengrong
    Jia, Zhong
    He, Dian
    OPEN LIFE SCIENCES, 2023, 18 (01):
  • [24] The Application of Artificial Intelligence in the Genetic Study of Alzheimer's Disease
    Mishra, Rohan
    Li, Bin
    AGING AND DISEASE, 2020, 11 (06): : 1567 - 1584
  • [25] Application of Artificial Intelligence in COVID-19 drug repurposing
    Mohanty, Sweta
    Rashid, Md Harun A., I
    Mridul, Mayank
    Mohanty, Chandana
    Swayamsiddha, Swati
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2020, 14 (05) : 1027 - 1031
  • [26] The Use of Artificial Intelligence to Predict the Development of Atrial Fibrillation
    Daniel Pipilas
    Samuel Freesun Friedman
    Shaan Khurshid
    Current Cardiology Reports, 2023, 25 : 381 - 389
  • [27] The Application of Artificial Intelligence in Ocean Development
    Yu, Yang
    Gu, LeiLei
    Wu, Xiangqi
    ENVIRONMENTAL ENGINEERING, PTS 1-4, 2014, 864-867 : 2116 - 2119
  • [28] The use of Artificial Intelligence Algorithms in drug development and clinical trials: A scoping review
    Pontes, Camila de Brito
    Netto, Antonio Valerio
    INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 2025, 195
  • [29] The application of artificial intelligence to drug sensitivity prediction
    Li, Xutong
    Wu, Xiaolong
    Wan, Xiaozhe
    Zhong, Feisheng
    Cui, Chen
    Chen, Yingjia
    Chen, Lifan
    Chen, Kaixian
    Jiang, Hualiang
    Zheng, Mingyue
    CHINESE SCIENCE BULLETIN-CHINESE, 2020, 65 (32): : 3551 - 3561
  • [30] The Use of Artificial Intelligence to Predict the Development of Atrial Fibrillation
    Pipilas, Daniel
    Friedman, Samuel Freesun
    Khurshid, Shaan
    CURRENT CARDIOLOGY REPORTS, 2023, 25 (05) : 381 - 389